Explainer: Sharpe Ratio – A key metric for risk-adjusted returns

The Sharpe Ratio, developed by Nobel laureate William F. Sharpe, is a key tool for evaluating mutual fund performance. It measures risk-adjusted returns, helping investors assess if the returns justify the risk taken. A higher Sharpe Ratio indicates better performance, while a lower ratio suggests poor risk-adjusted returns.

Technology sector poised for recovery; Coforge, HCL Tech could give 17-20% return in 1 year

The technology sector is set for a strong recovery, driven by increased investments and new technologies like Generative AI. Key sectors such as BFSI, healthcare, and manufacturing are expected to lead this growth. Service vendors and Global Capability Centers will play crucial roles in this expansion, with companies like HCL Technologies and Coforge positioned for […]

Hospital stocks’ growth outlook positive: HSBC

HSBC has given a ‘buy’ rating to Krishna Institute of Medical Sciences and Apollo Hospitals, while assigning a ‘reduce’ rating to Global Health and Narayana Hrudayalaya. The brokerage sees a positive growth outlook for the hospital sector due to rising demand for quality healthcare, with several hospitals planning significant bed additions in the coming years.

ICICI Security shareholder moves NCLAT against order on delisting

A shareholder has approached the NCLAT challenging the NCLT’s approval of ICICI Securities’ delisting application. The appeal cites misapplication of regulations, fraudulent voting, and non-transparency concerns. Quantum Mutual Fund and minority shareholders argue that the share swap negatively impacts them. An investor has also moved the Bombay High Court against SEBI’s decision.

India’s forex kitty jumps $5.2 billion to a fresh high of $689 billion

India’s foreign exchange reserves reached a new high of $689.235 billion at the end of September 6, according to the Reserve Bank of India. This marks the fourth consecutive weekly increase, with reserves rising by $5.248 billion in the last week alone. The rise is attributed to healthy dollar inflows and appreciation in other global […]

Biocon Biologics is planning to raise $950 million through overseas bonds

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from acquiring Viatris Inc.’s biosimilars business. The company has already prepaid $250 million and is exploring ways to reduce finance costs. The bond’s rating will determine its pricing.